Drug Type Small molecule drug |
Synonyms N-(2,6-diethyphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2- methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate + [5] |
Target |
Mechanism RPS27 inhibitors(ribosomal protein S27 inhibitors), TTK inhibitors(Dual specificity protein kinase TTK inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC35H39F3N8O3 |
InChIKeyJFOAJUGFHDCBJJ-UHFFFAOYSA-N |
CAS Registry1202055-32-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | - | - | |
Breast Cancer | Phase 2 | - | - | |
Metastatic Triple-Negative Breast Carcinoma | Phase 1 | FR | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 1 | NL | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 1 | JP | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 1 | BE | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 1 | JP | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 1 | FR | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 1 | NL | 04 Jan 2018 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 1 | BE | 04 Jan 2018 |
Phase 1/2 | 12 | (dose-finding) | (qsfucvqwgy) = dgrsaqzuud paqvhzcyxj (jmrwgmxuas ) View more | Positive | 28 Oct 2022 | ||
Not Applicable | - | (efhuxaxbbt) = oxraqhnpwc smqnsvlgpl (gxlcwetvpj ) View more | Positive | 28 Oct 2022 | |||
Phase 1 | 38 | (blzsyxzqib) = slzvgtpjmh pwjqgcitnz (oifhiwlmcc ) View more | - | 11 May 2022 |